Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis.
Breast cancer
Chemotherapy
HER2 breast
HER2 positive
Immunotherapy
NCDB
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
16
08
2021
accepted:
30
09
2021
pubmed:
17
10
2021
medline:
18
1
2022
entrez:
16
10
2021
Statut:
ppublish
Résumé
Approximately 20% of all breast cancers (BC) are HER2 amplified. In the APT trial, weekly paclitaxel/trastuzumab in node negative HER2+ BC with tumors < 3 cm was associated with a 7-year invasive disease-free survival of 93%. However, this was in the context of a non-randomized trial, and for pT1N0 HER2+ BC it remains unclear whether HER2 monotherapy would provide similar clinical outcomes to chemo-HER2 therapy. We hypothesized that adjuvant chemo-HER2 therapy would be associated with a modestly improved overall survival compared to HER2 monotherapy in patients with tumors < 2 cm. In the National Cancer Database (2004-2017), patients with a primary diagnosis of pT1N0M0 HER2+ BC, were separated into two groups: (i) HER2 monotherapy, i.e., trastuzumab, and (ii) chemo-HER2 therapy. A 3:1 propensity match was performed to balance patient selection bias between the two different cohorts. Long-term overall survival (OS) was compared between both groups. A total of 23,281 patients met the criteria. 22,268 (96.7%) received chemo-HER2 therapy and 1013 (4.4%) received HER2 monotherapy. Propensity match identified 1995 patients who received chemo-HER2 therapy, and 666 who received HER2 monotherapy. After matching, adjuvant chemo-HER2 therapy was associated with a modest survival advantage over HER2 monotherapy (5-year OS 94.1% vs. 90.6%, P = 0.041). Even though there is a modest OS advantage favoring adjuvant chemo-HER2 therapy in patients with pT1N0 HER2+ BC, HER2 monotherapy was associated with 5-year OS > 90%. Therefore, in select patients who have contraindications for cytotoxic chemotherapy, or decline adjuvant chemotherapy altogether, adjuvant trastuzumab monotherapy appears to be a reasonable alternative.
Identifiants
pubmed: 34655345
doi: 10.1007/s10549-021-06411-4
pii: 10.1007/s10549-021-06411-4
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-176Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Society AC (2021) Cancer Facts and Figures 2021. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html . Accessed 9 Aug 2021
Arteaga CL, Sliwkowski MX, Osborne CK et al (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9(1):16–32. https://doi.org/10.1038/nrclinonc.2011.177
doi: 10.1038/nrclinonc.2011.177
pubmed: 22124364
Mahtani R, Holmes FA, Badve S et al (2020) A roundtable discussion of the breast cancer therapy expert group (BCTEG): clinical developments and practice guidance on human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Clin Breast Cancer 20(3):e251–e260. https://doi.org/10.1016/j.clbc.2019.08.001
doi: 10.1016/j.clbc.2019.08.001
pubmed: 32139271
Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182. https://doi.org/10.1126/science.3798106
doi: 10.1126/science.3798106
pubmed: 3798106
Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712. https://doi.org/10.1126/science.2470152
doi: 10.1126/science.2470152
pubmed: 2470152
Sledge GW Jr (2018) HER2-positive breast cancer. The breast. Elsevier, Amsterdam, pp 763–768
doi: 10.1016/B978-0-323-35955-9.00056-8
Harries M, Smith I (2002) The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9(2):75–85. https://doi.org/10.1677/erc.0.0090075
doi: 10.1677/erc.0.0090075
pubmed: 12121832
Makhou I (2018) Therapeutic strategies for breast cancer. The breast. Elsevier, Amsterdam, pp 315–330
doi: 10.1016/B978-0-323-35955-9.00024-6
Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243. https://doi.org/10.1002/14651858.CD006243.pub2
doi: 10.1002/14651858.CD006243.pub2
Mitri Z, Constantine T, O’Regan R (2012) The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193. https://doi.org/10.1155/2012/743193
doi: 10.1155/2012/743193
pubmed: 23320171
pmcid: 3539433
Tolaney SM, Guo H, Pernas S et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 37(22):1868–1875. https://doi.org/10.1200/JCO.19.00066
doi: 10.1200/JCO.19.00066
pubmed: 30939096
pmcid: 7587424
Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141. https://doi.org/10.1056/NEJMoa1406281
doi: 10.1056/NEJMoa1406281
pubmed: 25564897
pmcid: 4313867
Vogel C, Cobleigh MA, Tripathy D et al (2001) First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 37(Suppl 1):25–29
doi: 10.1016/S0959-8049(00)00405-6
Piccart M, Procter M, Fumagalli D et al (2021) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol 39(13):1448–1457. https://doi.org/10.1200/JCO.20.01204
doi: 10.1200/JCO.20.01204
pubmed: 33539215
von Minckwitz G, Procter M, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131. https://doi.org/10.1056/NEJMoa1703643
doi: 10.1056/NEJMoa1703643
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH (2021) NCCN guidelines: breast cancer, version 8. 2021. J Natl Compr Cancer Netw 19:484–493
doi: 10.6004/jnccn.2021.0023
Sawaki M, Tokudome N, Mizuno T et al (2011) Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 41(5):709–712. https://doi.org/10.1093/jjco/hyr011
doi: 10.1093/jjco/hyr011
pubmed: 21355003
Howie LJ, Scher NS, Amiri-Kordestani L et al (2019) FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 25(10):2949–2955. https://doi.org/10.1158/1078-0432.CCR-18-3003
doi: 10.1158/1078-0432.CCR-18-3003
pubmed: 30552112
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. https://doi.org/10.1245/s10434-010-0985-4
doi: 10.1245/s10434-010-0985-4
pubmed: 20180029
Tolaney SM, Tayob N, Dang C et al (2021) Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol 39(21):2375–2385. https://doi.org/10.1200/JCO.20.03398
doi: 10.1200/JCO.20.03398
pubmed: 34077270
O’Sullivan CC, Bradbury I, Campbell C et al (2015) Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors </=2 cm: a meta-analysis of the randomized trastuzumab trials. J Clin Oncol 33(24):2600–2608. https://doi.org/10.1200/JCO.2015.60.8620
doi: 10.1200/JCO.2015.60.8620
pubmed: 26101239
pmcid: 4534523